Deucravacitinib (Sotyktu)

What is Deucravacitinib?

Deucravacitinib is an oral medication that has received FDA approval for the treatment of moderate to severe plaque psoriasis. It operates by inhibiting the TYK2 enzyme, a key component in the inflammatory response pathway implicated in psoriasis. This medication offers a targeted approach to managing the symptoms and progression of psoriasis. It will likely get FDA approval for psoriatic arthritis as well soon.

What are possible side effects of Deucravacitinib?

As with any medication, Deucravacitinib has a range of possible side effects. The most commonly reported ones include headache, upper respiratory tract infections, and elevated liver enzymes. In rare instances, patients may experience more serious side effects such as gastrointestinal issues or changes in blood cell counts. If you encounter any persistent or worsening symptoms, consult your healthcare provider for appropriate advice and management.

How is Deucravacitinib used?

Deucravacitinib is administered orally in pill form, usually once daily. It's essential to follow the prescribing healthcare provider's instructions for dosage and timing. Periodic blood tests may be recommended to monitor liver function, triglycerides (lipids) and other parameters. Most people will get a 75% improvement in their skin psoriasis after being on the medication for 16 weeks.